Zobrazeno 1 - 10
of 1 178
pro vyhledávání: '"LUIGI TAVAZZI"'
Autor:
Marco Canepa, Vincenzo De Marzo, Pietro Ameri, Roberto Ferrari, Luigi Tavazzi, Claudio Rapezzi, Italo Porto, Aldo Pietro Maggioni
Publikováno v:
ESC Heart Failure, Vol 10, Iss 5, Pp 3019-3027 (2023)
Abstract Aims This study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations. Methods and re
Externí odkaz:
https://doaj.org/article/6996026135914be794abd59e7c9f25e2
Autor:
Amr Abdin, Michel Komajda, Jeffrey S. Borer, Ian Ford, Luigi Tavazzi, Cécile Batailler, Karl Swedberg, Giuseppe M.C. Rosano, Felix Mahfoud, Michael Böhm, the SHIFT Investigators
Publikováno v:
ESC Heart Failure, Vol 10, Iss 5, Pp 2895-2902 (2023)
Abstract Aims Early start and patient profile‐oriented heart failure (HF) management has been recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment effects of ivabradine in HF patients with systolic blood pressure (
Externí odkaz:
https://doaj.org/article/57be3477d7f644d39cee58c4ae0dbbee
Publikováno v:
ESC Heart Failure, Vol 10, Iss 3, Pp 1972-1979 (2023)
Abstract Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrate
Externí odkaz:
https://doaj.org/article/9279b4d3272f47e79a87f7e80eab4be9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Martin R. Cowie, Jakob Schöpe, Stefan Wagenpfeil, Luigi Tavazzi, Michael Böhm, Piotr Ponikowski, Stefan D. Anker, Gerasimos S. Filippatos, Michel Komajda, QUALIFY Investigators
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 861-871 (2021)
Abstract Aims Failure to prescribe key medicines at evidence‐based doses is associated with increased mortality and hospitalization for patients with Heart Failure with reduced Ejection Fraction (HFrEF). We assessed titration patterns of guideline
Externí odkaz:
https://doaj.org/article/ecc42a376bb64ed886d748cdcb842a37
Autor:
Folkert W. Asselbergs, Arjan Sammani, Perry Elliott, Juan R. Gimeno, Luigi Tavazzi, Michael Tendera, Juan Pablo Kaski, Aldo P. Maggioni, Pawel P. Rubis, Ruxandra Jurcut, Tiina Heliö, Leonardo Calò, Gianfranco Sinagra, Marija Zdravkovic, Iacopo Olivotto, Aušra Kavoliūnienė, Cécile Laroche, Alida L.P. Caforio, Philippe Charron, Cardiomyopathy & Myocarditis Registry Investigators Group
Publikováno v:
ESC Heart Failure, Vol 8, Iss 1, Pp 95-105 (2021)
Abstract Aims Dilated cardiomyopathy (DCM) is a complex disease where genetics interplay with extrinsic factors. This study aims to compare the phenotype, management, and outcome of familial DCM (FDCM) and non‐familial (sporadic) DCM (SDCM) across
Externí odkaz:
https://doaj.org/article/4e2a90f75eb94e76a313e3119b06e3e2
Autor:
Giovanni Targher, Gianluigi Lunardi, Alessandro Mantovani, Jennifer Meessen, Stefano Bonapace, Pier Luigi Temporelli, Enrico Nicolis, Deborah Novelli, Antonio Conti, Luigi Tavazzi, Aldo Pietro Maggioni, Roberto Latini
Publikováno v:
ESC Heart Failure, Vol 7, Iss 6, Pp 3288-3297 (2020)
Abstract Aims Ceramides exert several biological activities that may contribute to the pathophysiology of cardiovascular disease and heart failure (HF). The association between plasma levels of distinct ceramides (that have been previously associated
Externí odkaz:
https://doaj.org/article/68e2281f859c4ac6b40ab30ca090be74
Autor:
Katarzyna Mizia‐Stec, Alida L.P. Caforio, Philippe Charron, Juan R. Gimeno, Perry Elliott, Juan Pablo Kaski, Aldo P. Maggioni, Luigi Tavazzi, Angelos G. Rigopoulos, Cecile Laroche, Attila Frigy, Elisabetta Zachara, Maria Luisa Pena‐Pena, Akinsanya Olusegun‐Joseph, Yigal Pinto, Simone Sala, Fabrizio Drago, Olga Blagova, Elena Reznik, Michał Tendera
Publikováno v:
ESC Heart Failure, Vol 7, Iss 6, Pp 3601-3609 (2020)
Abstract Aims Cardiomyopathies are a heterogeneous group of disorders that increase the risk for atrial fibrillation (AF). The aim of the study is to assess the prevalence of AF, anticoagulation management, and risk of stroke/transient ischaemic atta
Externí odkaz:
https://doaj.org/article/b7a3f2a7306041f3922c516fa4801b23
Autor:
Tiina Heliö, Perry Elliott, Juha W. Koskenvuo, Juan R. Gimeno, Luigi Tavazzi, Michal Tendera, Juan Pablo Kaski, Nicolas Mansencal, Zofia Bilińska, Gerry Carr‐White, Thibaud Damy, Andrea Frustaci, Ingrid Kindermann, Tomas Ripoll‐Vera, Jelena Čelutkienė, Anna Axelsson, Massimiliano Lorenzini, Aly Saad, Aldo P. Maggioni, Cécile Laroche, Alida L.P. Caforio, Philippe Charron, EORP Cardiomyopathy Registry Investigators Group
Publikováno v:
ESC Heart Failure, Vol 7, Iss 5, Pp 3013-3021 (2020)
Abstract Aims Cardiomyopathies comprise a heterogeneous group of diseases, often of genetic origin. We assessed the current practice of genetic counselling and testing in the prospective European Society of Cardiology EURObservational Research Progra
Externí odkaz:
https://doaj.org/article/485e31b51c3b43378da0d6af362f1427
Autor:
Nadia Bouabdallaoui, Eileen O'Meara, Virginie Bernier, Michel Komajda, Karl Swedberg, Luigi Tavazzi, Jeffrey S. Borer, Michael Bohm, Ian Ford, Jean‐Claude Tardif
Publikováno v:
ESC Heart Failure, Vol 6, Iss 6, Pp 1199-1207 (2019)
Abstract Aims Ivabradine has been approved in heart failure with reduced ejection fraction (HFrEF) and elevated heart rate despite guideline‐directed medical therapy (GDMT) to reduce cardiovascular (CV) death and hospitalization for worsening HF. T
Externí odkaz:
https://doaj.org/article/4f7a86c02140492eb8b03de16469e2c0